Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.52 |
| ▸ | KDR | P35968 | 4/20 | 0.49 |
| ▸ | FLT1 | P17948 | 2/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.48 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5567997 | 0.89 | EGFR (0.48) | EGFRERBB2 | |
| SCHEMBL5567991 | 0.88 | EGFR (0.56) | EGFRERBB2KDRFLT1FGFR1 | |
| SCHEMBL118997 | 0.81 | EGFR (0.80) | EGFRERBB2KDRFLT1FGFR1 | |
| SCHEMBL29623442 | 0.81 | EGFR (0.80) | EGFRERBB2KDRFLT1FGFR1 | |
| SCHEMBL5568727 | 0.80 | EGFR (0.49) | EGFRERBB2KDREPHA2EPHB4 | |
| SCHEMBL1446465 | 0.77 | EGFR (0.78) | EGFRERBB2KDRFLT1EPHA2 | |
| SCHEMBL1446468 | 0.77 | EGFR (0.78) | EGFRERBB2KDRFLT1EPHA2 | |
| Hydrochloric Acid SCHEMBL4032016 | 0.77 | EGFR (0.67) | EGFRERBB2KDR | |
| SCHEMBL2270647 | 0.77 | EGFR (0.72) | EGFRERBB2KDRFLT1FGFR1 | |
| SCHEMBL5568726 | 0.76 | EGFR (0.59) | EGFRERBB2KDREPHA2EPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | claimed |
| EP-1664028-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | claimed |
| WO-2005026151-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | claimed |
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| EP-1664028-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026151-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ABL1, ERBB2, LCK | EGFR 15/4885ERBB2 2/4885KDR 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.